Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
Anna Mae Diehl, Christopher P. Day
New England Journal of Medicine (2017) Vol. 377, Iss. 21, pp. 2063-2072
Closed Access | Times Cited: 1088

Showing 26-50 of 1088 citing articles:

PPAR Agonists and Metabolic Syndrome: An Established Role?
Margherita Botta, Matteo Audano, Amirhossein Sahebkar, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 4, pp. 1197-1197
Open Access | Times Cited: 213
Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Jinhua Yan, Bin Yao, Hongyu Kuang, et al.
Hepatology (2018) Vol. 69, Iss. 6, pp. 2414-2426
Open Access | Times Cited: 205
Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis
Yong Rao, Zhiqi Kuang, Chan Li, et al.
Gut Microbes (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 205
Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors
Oriol Juanola, Sebastián Martínez‐López, Rubén Francés, et al.
International Journal of Environmental Research and Public Health (2021) Vol. 18, Iss. 10, pp. 5227-5227
Open Access | Times Cited: 194
Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments
Cheng Peng, Alastair G. Stewart, Owen L. Woodman, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 180
Beneficial Effects of Betaine: A Comprehensive Review
Madan Kumar Arumugam, Matthew C. Paal, Terrence M. Donohue, et al.
Biology (2021) Vol. 10, Iss. 6, pp. 456-456
Open Access | Times Cited: 177
Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives
Natalia G. Vallianou, Gerasimos Socrates Christodoulatos, Ιrene Karampela, et al.
Biomolecules (2021) Vol. 12, Iss. 1, pp. 56-56
Open Access | Times Cited: 176
Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China)
Jian‐Gao Fan, Lai Wei, Hui Zhuang
Journal of Digestive Diseases (2018) Vol. 20, Iss. 4, pp. 163-173
Closed Access | Times Cited: 174
Non‐alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management
D. Huang, Jason Behary, Amany Zekry
Internal Medicine Journal (2019) Vol. 50, Iss. 9, pp. 1038-1047
Closed Access | Times Cited: 172
FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
Erik J. Tillman, Timothy P. Rolph
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 161
Gut microbiome–targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression
Suzanne R. Sharpton, Bharat Maraj, Emily Harding‐Theobald, et al.
American Journal of Clinical Nutrition (2019) Vol. 110, Iss. 1, pp. 139-149
Open Access | Times Cited: 157
Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis—Literature Review
Abdulrahman Ismaiel, Dan L. Dumitraşcu
Frontiers in Medicine (2019) Vol. 6
Open Access | Times Cited: 152
Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease
Sonja Lang, Münevver Demir, Anna Martin, et al.
Gastroenterology (2020) Vol. 159, Iss. 5, pp. 1839-1852
Open Access | Times Cited: 149
XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis
Aleksandra Deczkowska, Eyal David, Pierluigi Ramadori, et al.
Nature Medicine (2021) Vol. 27, Iss. 6, pp. 1043-1054
Open Access | Times Cited: 141
Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH
Stephen A. Harrison, Mustafa R. Bashir, Sam E. Moussa, et al.
Hepatology Communications (2021) Vol. 5, Iss. 4, pp. 573-588
Open Access | Times Cited: 139
Microbiome-derived ethanol in nonalcoholic fatty liver disease
Abraham S. Meijnikman, Mark Davids, Hilde Herrema, et al.
Nature Medicine (2022) Vol. 28, Iss. 10, pp. 2100-2106
Closed Access | Times Cited: 129
The fecal mycobiome in non-alcoholic fatty liver disease
Münevver Demir, Sonja Lang, Phillipp Hartmann, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 4, pp. 788-799
Open Access | Times Cited: 121
A Systematic Review of Animal Models of NAFLD Finds High‐Fat, High‐Fructose Diets Most Closely Resemble Human NAFLD
Yu Ri Im, Harriet Hunter, Dana de Gracia Hahn, et al.
Hepatology (2021) Vol. 74, Iss. 4, pp. 1884-1901
Open Access | Times Cited: 119
Disease burden and economic impact of diagnosed non‐alcoholic steatohepatitis in five European countries in 2018: A cost‐of‐illness analysis
Jörn M. Schattenberg, Jeffrey V. Lazarus, Philip N. Newsome, et al.
Liver International (2021) Vol. 41, Iss. 6, pp. 1227-1242
Open Access | Times Cited: 107
Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial
Arun J. Sanyal, Patricia López, Eric Lawitz, et al.
Nature Medicine (2023) Vol. 29, Iss. 2, pp. 392-400
Open Access | Times Cited: 103
Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)
Yuan-ye Qiu, Jing Zhang, Fanyi Zeng, et al.
Pharmacological Research (2023) Vol. 192, pp. 106786-106786
Open Access | Times Cited: 96
Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease
Tingying Jiao, Yuandi Ma, Xiaozhen Guo, et al.
Acta Pharmacologica Sinica (2022) Vol. 43, Iss. 5, pp. 1103-1119
Open Access | Times Cited: 72
Resmetirom: An Orally Administered, Small-molecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
Gres Karim, Meena B. Bansal
touchREVIEWS in Endocrinology (2023) Vol. 19, Iss. 1, pp. 60-60
Open Access | Times Cited: 66
Natural history of metabolic dysfunction-associated steatotic liver disease
Vasileios Lekakis, George Papatheodoridis
European Journal of Internal Medicine (2023) Vol. 122, pp. 3-10
Closed Access | Times Cited: 54
Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)
Shuang Wang, Scott L. Friedman
Science Translational Medicine (2023) Vol. 15, Iss. 716
Open Access | Times Cited: 50

Scroll to top